BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

126 related articles for article (PubMed ID: 29695404)

  • 1. Establishment and Characteristics of a Novel Mantle Cell Lymphoma-derived Cell Line and a Bendamustine-resistant Subline.
    Takimoto-Shimomura T; Nagoshi H; Maegawa S; Fujibayashi Y; Tsukamoto T; Matsumura-Kimoto Y; Mizuno Y; Chinen Y; Mizutani S; Shimura Y; Horiike S; Taniwaki M; Kobayashi T; Kuroda J
    Cancer Genomics Proteomics; 2018; 15(3):213-223. PubMed ID: 29695404
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Synergistic Cytotoxicity of Bendamustine and the BTK Inhibitor in a Mantle Cell Lymphoma Cell Line.
    Hagiwara K; Tokunaga T; Iida H; Nagai H
    Anticancer Res; 2015 Dec; 35(12):6679-84. PubMed ID: 26637884
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Inhibition of Lyn is a promising treatment for mantle cell lymphoma with bortezomib resistance.
    Kim A; Seong KM; Kang HJ; Park S; Lee SS
    Oncotarget; 2015 Nov; 6(35):38225-38. PubMed ID: 26517678
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Characterization of a mantle cell lymphoma cell line resistant to the Chk1 inhibitor PF-00477736.
    Restelli V; Chilà R; Lupi M; Rinaldi A; Kwee I; Bertoni F; Damia G; Carrassa L
    Oncotarget; 2015 Nov; 6(35):37229-40. PubMed ID: 26439697
    [TBL] [Abstract][Full Text] [Related]  

  • 5. B7-H3 silencing inhibits tumor progression of mantle cell lymphoma and enhances chemosensitivity.
    Zhang W; Wang Y; Wang J; Dong F; Zhu M; Wan W; Li H; Wu F; Yan X; Ke X
    Int J Oncol; 2015; 46(6):2562-72. PubMed ID: 25872657
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Bendamustine is effective in p53-deficient B-cell neoplasms and requires oxidative stress and caspase-independent signaling.
    Roué G; López-Guerra M; Milpied P; Pérez-Galán P; Villamor N; Montserrat E; Campo E; Colomer D
    Clin Cancer Res; 2008 Nov; 14(21):6907-15. PubMed ID: 18980985
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Methylation of PLK-1 Potentially Drives Bendamustine Resistance in Leukemia Cells.
    Itabashi T; Ueda T; Fukunaga R; Asano T; Itoh Y
    J Nippon Med Sch; 2024 May; 91(2):162-171. PubMed ID: 38072417
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Combination of Pim kinase inhibitor SGI-1776 and bendamustine in B-cell lymphoma.
    Yang Q; Chen LS; Neelapu SS; Gandhi V
    Clin Lymphoma Myeloma Leuk; 2013 Sep; 13 Suppl 2(0 2):S355-62. PubMed ID: 24290221
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The discovery and the development of bendamustine for the treatment of non-Hodgkin lymphoma.
    Munakata W; Tobinai K
    Expert Opin Drug Discov; 2016 Nov; 11(11):1123-1130. PubMed ID: 27598460
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Bendamustine-rituximab in mantle cell lymphoma.
    Lipsky A; Martin P
    Lancet Haematol; 2017 Jan; 4(1):e2-e3. PubMed ID: 27927585
    [No Abstract]   [Full Text] [Related]  

  • 11. Stem-like tumor cells confer drug resistant properties to mantle cell lymphoma.
    Jung HJ; Chen Z; McCarty N
    Leuk Lymphoma; 2011 Jun; 52(6):1066-79. PubMed ID: 21599592
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Single-cell RNA-seq reveals the immune escape and drug resistance mechanisms of mantle cell lymphoma.
    Wang L; Mo S; Li X; He Y; Yang J
    Cancer Biol Med; 2020 Aug; 17(3):726-739. PubMed ID: 32944402
    [No Abstract]   [Full Text] [Related]  

  • 13. The dual PI3K and mTOR inhibitor NVP-BEZ235 exhibits anti-proliferative activity and overcomes bortezomib resistance in mantle cell lymphoma cells.
    Kim A; Park S; Lee JE; Jang WS; Lee SJ; Kang HJ; Lee SS
    Leuk Res; 2012 Jul; 36(7):912-20. PubMed ID: 22560334
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Temsirolimus acts as additive with bendamustine in aggressive lymphoma.
    Zoellner AK; Weiglein T; Hutter G; Zimmermann Y; Cieplik HC; Hess G; Dreyling M
    Ann Hematol; 2016 Feb; 95(3):403-7. PubMed ID: 26658770
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The STAT3 inhibitor WP1066 synergizes with vorinostat to induce apoptosis of mantle cell lymphoma cells.
    Lu K; Chen N; Zhou XX; Ge XL; Feng LL; Li PP; Li XY; Geng LY; Wang X
    Biochem Biophys Res Commun; 2015 Aug; 464(1):292-8. PubMed ID: 26116769
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Targeting ABCB1 (MDR1) in multi-drug resistant osteosarcoma cells using the CRISPR-Cas9 system to reverse drug resistance.
    Liu T; Li Z; Zhang Q; De Amorim Bernstein K; Lozano-Calderon S; Choy E; Hornicek FJ; Duan Z
    Oncotarget; 2016 Dec; 7(50):83502-83513. PubMed ID: 27835872
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A lowered 26S proteasome activity correlates with mantle lymphoma cell lines resistance to genotoxic stress.
    Ben Younes K; Body S; Costé É; Viailly PJ; Miloudi H; Coudre C; Jardin F; Ben Aissa-Fennira F; Sola B
    BMC Cancer; 2017 Aug; 17(1):538. PubMed ID: 28797244
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Multidrug resistance reversing activity of newly developed phenothiazines on P-glycoprotein (ABCB1)-related resistance of mouse T-lymphoma cells.
    Spengler G; Takács D; Horváth A; Riedl Z; Hajós G; Amaral L; Molnár J
    Anticancer Res; 2014 Apr; 34(4):1737-41. PubMed ID: 24692704
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Reversal effect of quercetin on multidrug resistance via FZD7/β-catenin pathway in hepatocellular carcinoma cells.
    Chen Z; Huang C; Ma T; Jiang L; Tang L; Shi T; Zhang S; Zhang L; Zhu P; Li J; Shen A
    Phytomedicine; 2018 Apr; 43():37-45. PubMed ID: 29747752
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pharmacokinetic profile and first preliminary clinical evaluation of bendamustine in Taiwanese patients with heavily pretreated indolent B-cell non-Hodgkin lymphoma and mantle cell lymphoma.
    Hsiao LT; Tien HF; Kuo CY; Wu JH; Hou HA; Wang MC; Liu CY; Chen PM; Chiou TJ
    Hematol Oncol; 2015 Dec; 33(4):136-44. PubMed ID: 25111959
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.